国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

FDA approves new drug for blood cancer

Source: Xinhua| 2018-11-29 09:59:46|Editor: Liangyu
Video PlayerClose

WASHINGTON, Nov. 28 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Wednesday a new drug, Xospata, for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

AML is a rapidly progressing cancer that crowds out normal cells in the bone marrow and bloodstream, resulting in low numbers of normal blood cells and a continuous need for transfusions.

"Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," said Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

"Xospata targets this gene and is the first drug to be approved that can be used alone in treating patients with AML having a FLT3 mutation who have relapsed or who don't respond to initial treatment."

The efficiency of Xospata was studied in a clinical trial of 138 patients with relapsed or refractory AML having a confirmed FLT3 mutation.

Twenty-one percent of patients achieved complete remission or complete remission with partial hematologic recovery with treatment, according to FDA.

Of the 106 patients who required red blood cell or platelet transfusions at the start of treatment with Xospata, 31 percent became transfusion-free for at least 56 days, according to FDA.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011100001376391851
主站蜘蛛池模板: 南投县| 霍州市| 江西省| 太仓市| 三亚市| 深圳市| 广安市| 岗巴县| 高雄市| 南澳县| 稷山县| 平远县| 禹州市| 涟水县| 南郑县| 周宁县| 永泰县| 郁南县| 金沙县| 外汇| 灵寿县| 武平县| 罗田县| 蒙山县| 中江县| 江达县| 延川县| 银川市| 安塞县| 长沙县| 漳浦县| 朝阳区| 两当县| 南华县| 崇州市| 长治县| 遂宁市| 泽普县| 台前县| 花垣县| 台东县|